EGFR and non-small cell lung carcinoma: Currently, precision treatment options for lung cancer primarily depend on its histologic subtype and genetic characteristics (Caso et al., 2020), for instance, tyrosine kinase inhibitors (TKIs) are preferred for patients with mutations or fusions in genes such as the epidermal growth factor receptor (EGFR-Mutant NSCLC, 2023).